Abstract
Purpose of Review
To provide clinicians with an understanding of risk factors associated with fatal anaphylaxis, and to promote individualized management plans with patients based upon key aspects of their clinical history.
Recent Findings
While anaphylaxis can affect a significant percentage of the general population, death from anaphylaxis remains a rare outcome. The presence of asthma and peanut or tree nut allergy is associated with higher risk for severe or fatal anaphylaxis from foods. Specific triggers (medications, venom), underlying comorbid conditions, age, and use of some medications can also impact risk and warrant different counseling and management strategies.
Summary
Anaphylaxis is a rapidly progressive systemic reaction with multiple different causes and encompasses a wide degree of severity in clinical presentation and risk for future episodes. Individualized management, discussion of risk, and shared decision making should occur with each patient and in consideration of their personal risk factors.
Similar content being viewed by others
Abbreviations
- EIA:
-
Exercise-induced anaphylaxis
- ICD-10:
-
International Classification of Diseases
- IgE:
-
Immunoglobulin E
- NMBAs:
-
Neuromuscular blocking agents
- NSAIDs:
-
Nonsteroidal anti-inflammatory drugs
- SDM:
-
Shared decision making
References
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
•• Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117(2):391–7 A comprehensive review of anaphylaxis diagnostic criteria and practical application in the clinical setting.
Simons FE, Ardusso LR, Bilò MB, Cardona V, Ebisawa M, El-Gamal YM, et al. International consensus on (ICON) anaphylaxis. World Allergy Organ J. 2014;7(1):9.
Brown SG, Stone SF, Fatovich DM, Burrows SA, Holdgate A, Celenza A, et al. Anaphylaxis: clinical patterns, mediator release, and severity. J Allergy Clin Immunol. 2013;132(5):1141–1149.e5.
Santos AF, Shreffler WG. Road map for the clinical application of the basophil activation test in food allergy. Clin Exp Allergy. 2017;47(9):1115–24.
Wood RA, Camargo CA Jr, Lieberman P, Sampson HA, Schwartz LB, Zitt M, et al. Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133(2):461–7.
Pouessel G, Turner PJ, Worm M, Cardona V, Deschildre A, Beaudouin E, et al. Food-induced fatal anaphylaxis: from epidemiological data to general prevention strategies. Clin Exp Allergy. 2018;48(12):1584–93.
Turner PJ, Gowland MH, Sharma V, Ierodiakonou D, Harper N, Garcez T, et al. Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012. J Allergy Clin Immunol. 2015;135(4):956–63.e1.
Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations. J Allergy Clin Immunol. 2014;134(6):1318–1328.e7.
Dorris S. Fatal food anaphylaxis: registering a rare outcome. Ann Allergy Asthma Immunol. 2020;124(5):445–6.
Turner PJ, Jerschow E, Umasunthar T, Lin R, Campbell DE, Boyle RJ. Fatal anaphylaxis: mortality rate and risk factors. J Allergy Clin Immunol Pract. 2017;5(5):1169–78.
Michelson KA, Dribin TE, Vyles D, Neuman MI. Trends in emergency care for anaphylaxis. J Allergy Clin Immunol Pract. 2020;8(2):767–768.e2.
Grabenhenrich LB, Dölle S, Moneret-Vautrin A, Köhli A, Lange L, Spindler T, et al. Anaphylaxis in children and adolescents: the European Anaphylaxis Registry. J Allergy Clin Immunol. 2016;137(4):1128–1137.e1.
Worm M, Moneret-Vautrin A, Scherer K, Lang R, Fernandez-Rivas M, Cardona V, et al. First European data from the network of severe allergic reactions (NORA). Allergy. 2014;69(10):1397–404.
Liew WK, Williamson E, Tang ML. Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol. 2009;123(2):434–42.
Golden DBK. Anaphylaxis: recognizing risk and targeting treatment. J Allergy Clin Immunol Pract. 2017 Sep-Oct;5(5):1224–6.
Stukus DR. Early Recognition of anaphylaxis in high risk settings. In: Ellis A, editor. Anaphylaxis – a practical guide. New York: Springer Science+Business Media; 2019.
Mullins RJ, Wainstein BK, Barnes EH, Liew WK, Campbell DE. Increases in anaphylaxis fatalities in Australia from 1997 to 2013. Clin Exp Allergy. 2016;46(8):1099–110.
Reitter M, Petitpain N, Latarche C, Cottin J, Massy N, Demoly P. et al; French Network of Regional Pharmacovigilance Centres. Fatal anaphylaxis with neuromuscular blocking agents: a risk factor and management analysis. Allergy. 2014;69(7):954–9.
Gülen T, Ljung C, Nilsson G, Akin C. Risk factor analysis of anaphylactic reactions in patients with systemic mastocytosis. J Allergy Clin Immunol Pract. 2017;5(5):1248–55.
Lee S, Hess EP, Nestler DM, Bellamkonda Athmaram VR, Bellolio MF, Decker WW, et al. Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis. J Allergy Clin Immunol. 2013;131(4):1103–8.
Greenberger PA. Fatal and near-fatal anaphylaxis: factors that can worsen or contribute to fatal outcomes. Immunol Allergy Clin N Am. 2015;35(2):375–86.
Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med. 1992;327(6):380–4.
Ma L, Danoff TM, Borish L. Case fatality and population mortality associated with anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133(4):1075–83.
Xu YS, Kastner M, Harada L, Xu A, Salter J, Waserman S. Anaphylaxis-related deaths in Ontario: a retrospective review of cases from 1986 to 2011. Allergy, Asthma Clin Immunol. 2014;10(1):38.
Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107(1):191–3.
Bock SA, Muñoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol. 2007;119(4):1016–8.
Pumphrey RS, Gowland MH. Further fatal allergic reactions to food in the United Kingdom, 1999-2006. J Allergy Clin Immunol. 2007;119(4):1018–9.
Pouessel G, Claverie C, Labreuche J, Dorkenoo A, Renaudin JM, Eb M, et al. Fatal anaphylaxis in France: analysis of national anaphylaxis data, 1979-2011. J Allergy Clin Immunol. 2017;140(2):610–612.e2.
Turner PJ, Baumert JL, Beyer K, Boyle RJ, Chan CH, Clark AT, et al. Can we identify patients at risk of life-threatening allergic reactions to food? Allergy. 2016;71(9):1241–55.
Umasunthar T, Leonardi-Bee J, Hodes M, Turner PJ, Gore C, Habibi P, et al. Incidence of fatal food anaphylaxis in people with food allergy: a systematic review and meta-analysis. Clin Exp Allergy. 2013;43(12):1333–41.
Grabenhenrich LB, Dölle S, Ruëff F, Renaudin JM, Scherer K, Pföhler C, et al. Epinephrine in severe allergic reactions: the european anaphylaxis register. J Allergy Clin Immunol Pract. 2018;6(6):1898–1906.e1.
Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy. 2000;30(8):1144–50.
Shaker MS, Schwartz J, Ferguson M. An update on the impact of food allergy on anxiety and quality of life. Curr Opin Pediatr. 2017;29(4):497–502.
Bilo MB, Corsi A, Martini M, Penza E, Grippo F, Bignardi D. Fatal anaphylaxis in Italy: analysis of cause-of-death national data, 2004-2016. Allergy. 2020.
•• Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010;105(4):259-73. Thorough reference for the presentation, evaluation, and management of various forms of drug hypersensitivity reactions.
Kuruvilla M, Khan DA. Anaphylaxis to drugs. Immunol Allergy Clin N Am. 2015;35(2):303–19.
Saff RR. Immediate local anesthetic reactions: too quick to point the finger? J Allergy Clin Immunol Pract. 2018;6(4):1224–5.
Motosue MS, Bellolio MF, Van Houten HK, Shah ND, Campbell RL. Risk factors for severe anaphylaxis in the United States. Ann Allergy Asthma Immunol. 2017;119(4):356–61 e2.
Hsu Blatman KS, Hepner DL. Current knowledge and management of hypersensitivity to perioperative drugs and radiocontrast media. J Allergy Clin Immunol Pract. 2017;5(3):587–92.
Volcheck GW, Hepner DL. Identification and management of perioperative anaphylaxis. J Allergy Clin Immunol Pract. 2019;7(7):2134–42.
•• Golden DB, Demain J, Freeman T, Graft D, Tankersley M, Tracy J, et al. Stinging insect hypersensitivity: A practice parameter update 2016. Ann Allergy Asthma Immunol. 2017;118(1):28–54 The go-to source for comprehensive information regarding venom allergy, including presentation, evaluation, risk factors, and treatment.
Golden DB. Anaphylaxis to insect stings. Immunol Allergy Clin N Am. 2015;35(2):287–302.
Stoevesandt J, Sturm GJ, Bonadonna P, Oude Elberink JNG, Trautmann A. Risk factors and indicators of severe systemic insect sting reactions. Allergy. 2020;75(3):535–45.
Rueff F, Przybilla B, Bilo MB, Muller U, Scheipl F, Aberer W, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol. 2009;124(5):1047–54.
Worm M, Francuzik W, Renaudin JM, Bilo MB, Cardona V, Scherer Hofmeier K, et al. Factors increasing the risk for a severe reaction in anaphylaxis: an analysis of data from The European Anaphylaxis Registry. Allergy. 2018;73(6):1322–30.
Chapsa M, Roensch H, Langner M, Beissert S, Bauer A. Predictors of severe anaphylaxis in Hymenoptera venom allergy: the importance of absence of urticaria and angioedema. Ann Allergy Asthma Immunol. 2020;125(1):72–7.
Bonadonna P, Scaffidi L. Hymenoptera anaphylaxis as a clonal mast cell disorder. Immunol Allergy Clin N Am. 2018;38(3):455–68.
Zanotti R, Lombardo C, Passalacqua G, Caimmi C, Bonifacio M, De Matteis G, et al. Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels. J Allergy Clin Immunol. 2015;136(1):135–9.
Vos B, van Anrooij B, van Doormaal JJ, Dubois AEJ, Oude Elberink JNG. Fatal anaphylaxis to yellow jacket stings in mastocytosis: options for identification and treatment of at-risk patients. J Allergy Clin Immunol Pract. 2017;5(5):1264–71.
Bonadonna P, Zanotti R, Pagani M, Bonifacio M, Scaffidi L, Olivieri E, et al. Anaphylactic reactions after discontinuation of hymenoptera venom immunotherapy: a clonal mast cell disorder should be suspected. J Allergy Clin Immunol Pract. 2018;6(4):1368–72.
•• McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. J Allergy Clin Immunol. 2018;141(2):463–72 Thorough review of adverse reactions to vaccines, particularly the causes and presentation of hypersensitivity reactions.
Su JR, Moro PL, Ng CS, Lewis PW, Said MA, Cano MV. Anaphylaxis after vaccination reported to the vaccine adverse event reporting system, 1990-2016. J Allergy Clin Immunol. 2019;143(4):1465–73.
Bohlke K, Davis RL, Marcy SM, Braun MM, DeStefano F, Black SB, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003;112(4):815–20.
McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016;137(3):868–78.
Pool V, Braun MM, Kelso JM, Mootrey G, Chen RT, Yunginger JW, et al. Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States. Pediatrics. 2002;110(6):e71.
Kelso JM, Greenhawt MJ, Li JT, Nicklas RA, Bernstein DI, Blessing-Moore J, et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol. 2012;130(1):25–43.
Greenhawt M, Turner PJ, Kelso JM. Administration of influenza vaccines to egg allergic recipients: a practice parameter update 2017. Ann Allergy Asthma Immunol. 2018;120(1):49–52.
Geller M. Clinical management of exercise-induced anaphylaxis and cholinergic urticaria. J Allergy Clin Immunol Pract. 2020;8(7):2209–14.
Feldweg AM. Exercise-induced anaphylaxis. Immunol Allergy Clin N Am. 2015;35(2):261–75.
Yee CSK, El Khoury K, Albuhairi S, Broyles A, Schneider L, Rachid R. Acquired cold-induced urticaria in pediatric patients: a 22-year experience in a tertiary care center (1996-2017). J Allergy Clin Immunol Pract. 2019;7(3):1024–31 e3.
Jain SV, Mullins RJ. Cold urticaria: a 20-year follow-up study. J Eur Acad Dermatol Venereol. 2016;30(12):2066–71.
Katsarou-Katsari A, Makris M, Lagogianni E, Gregoriou S, Theoharides T, Kalogeromitros D. Clinical features and natural history of acquired cold urticaria in a tertiary referral hospital: a 10-year prospective study. J Eur Acad Dermatol Venereol. 2008;22(12):1405–11.
Neittaanmäki H. Cold urticaria. Clinical findings in 220 patients. J Am Acad Dermatol. 1985;13(4):636–44.
Maurer M, Fluhr JW, Khan DA. How to approach chronic inducible urticaria. J Allergy Clin Immunol Pract. 2018;6(4):1119–30.
•• Greenhawt M, Shaker M, Wang J, Oppenheimer JJ, Sicherer S, Keet C, et al. Peanut allergy diagnosis- a 2020 practice parameter update, systematic review, and GRADE analysis. J Allergy Clin Immunol. 2020;15:S0091-6749(20)31137-4 Thorough review of peanut allergy diagnostic testing and best approach to using each test as well as proper interpretation.
Sampson HA, Aceves S, Bock SA, James J, Jones S, Lang D, et al. Food allergy: a practice parameter update-2014. J Allergy Clin Immunol. 2014;134(5):1016–25.e43.
Fitzhugh DJ, Bernstein DI. Should epinephrine autoinjectors be prescribed to all patients on subcutaneous immunotherapy? J Allergy Clin Immunol Pract. 2016;4(5):862–7.
Sun D, Cafone J, Shaker M, Greenhawt M. The cost-effectiveness of requiring universal vs contextual self-injectable epinephrine autoinjector for allergen immunotherapy. Ann Allergy Asthma Immunol. 2019;123(6):582–9.
Wang Y, McKee M, Torbica A, Stuckler D. Systematic literature review on the spread of health-related misinformation on social media. Soc Sci Med. 2019;240:112552.
Blaiss MS, Steven GC, Bender B, Bukstein DA, Meltzer EO, Winders T. Shared decision making for the allergist. Ann Allergy Asthma Immunol. 2019;122(5):463–70.
Tonelli MR, Sullivan MD. Person-centred shared decision making. J Eval Clin Pract. 2019;25(6):1057–62.
Greenhawt M, Shaker M, Winders T, Bukstein DA, Davis RS, Oppenheimer J, et al. Development and acceptability of a shared decision-making tool for commercial peanut allergy therapies. Ann Allergy Asthma Immunol. 2020;125(1):90–6.
Anagnostou A, Hourihane JO, Greenhawt M. The role of shared decision making in pediatric food allergy management. J Allergy Clin Immunol Pract. 2020;8(1):46–51.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare no conflicts of interest relevant to this manuscript.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Autoimmunity
Rights and permissions
About this article
Cite this article
Mikhail, I., Stukus, D.R. & Prince, B.T. Fatal Anaphylaxis: Epidemiology and Risk Factors. Curr Allergy Asthma Rep 21, 28 (2021). https://doi.org/10.1007/s11882-021-01006-x
Accepted:
Published:
DOI: https://doi.org/10.1007/s11882-021-01006-x